Effects of immunosuppression on alpha and beta cell renewal in transplanted mouse islets

Diabetologia

Volumn 56, Issue 7, 2013, Pages 1596-1604

  Krautz, C ^a   Wolk, S ^a   Steffen, A ^a   Knoch, K P ^a   Ceglarek, U ^b   Thiery, J ^b   Bornstein, S ^a   Saeger, H D ^a   Solimena, M ^a,c   Kersting, S ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

Author keywords

Cell proliferation; Drug monitoring; Glucagon secreting cells; Immunosuppression; Insulin secreting cells; Islets transplantation; Mice

Indexed keywords

EVEROLIMUS; GLUCOSE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL PROLIFERATION; CELL RENEWAL; CELL SIZE; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GRAFT DYSFUNCTION; IMMUNOSUPPRESSIVE TREATMENT; INSULINEMIA; MOUSE; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; BLOOD GLUCOSE; CELL PROLIFERATION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED C57BL;

EID: 84878855292     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2895-z     Document Type: Article

References (31)

1. Roelen DL, Huurman VA, Hilbrands R et al (2009) Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. Clin Exp Immunol 156:141-148
2. Korsgren O, Lundgren T, Felldin M et al (2008) Optimising islet engraftment is critical for successful clinical islet transplantation. Diabetologia 51:227-232
3. Nir T, Melton DA, Dor Y (2007) Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 117:2553-2561
4. Dor Y, Brown J, Martinez OI, Melton DA (2004) Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429:41-46
5. Collombat P, Mansouri A (2009) Turning on the beta-cell identity in the pancreas. Cell Cycle 8:3450-3451
6. Thorel F, Népote V, Avril I et al (2010) Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 464:1149-1154
7. Zahr E, Molano RD, Pileggi A et al (2008) Rapamycin impairs beta-cell proliferation in vivo. Transplant Proc 40:436-437
8. -/- mice despite severe hypercholesterolemia. Atherosclerosis 198:39-48
9. Gotoh M, Maki T, Kiyoizumi T, Satomi S, Monaco AP (1985) An improved method for isolation of mouse pancreatic islets. Transplantation 40:437-438
10. Sato E, Yano I, Shimomura M et al (2009) Larger dosage required for everolimus than sirolimus to maintain same blood concentration in two pancreatic islet transplant patients with tacrolimus. Drug Metab Pharmacokinet 24:175-179
11. Alonso LC, Yokoe T, Zhang P et al (2007) Glucose infusion in mice: a new model to induce beta-cell replication. Diabetes 56:1792-1801
12. Mziaut H, Kersting S, Knoch KP et al (2008) ICA512 signaling enhances pancreatic beta-cell proliferation by regulating cyclins D through STATs. Proc Natl Acad Sci U S A 105:674-679
13. Bonner-Weir S (2001) Beta-cell turnover: its assessment and implications. Diabetes 50(1):S20-S24
14. McDaniel ML, Marshall CA, Pappan KL, Kwon G (2002) Metabolic and autocrine regulation of the mammalian target of rapamycin by pancreatic beta-cells. Diabetes 51:2877-2885
15. Rother KI, Harlan DM (2004) Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J Clin Invest 114:877-883
16. Bartolomé A, Guillén C, Benito M (2010) Role of the TSC1-TSC2 complex in the integration of insulin and glucose signaling involved in pancreatic beta-cell proliferation. Endocrinology 151:3084-3094
17. Wang X, Beugnet A, Murakami M, Yamanaka S, Proud CG (2005) Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol Cell Biol 25:2558-2572
18. Pende M, Kozma SC, Jaquet M et al (2000) Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 408:994-997
19. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18:1926-1945
20. Heit JJ (2007) Calcineurin/NFAT signaling in the beta-cell: from diabetes to new therapeutics. BioEssays 29:1011-1021
21. Li G, Segu VB, Rabaglia ME, Luo RH, Kowluru A, Metz SA (1998) Prolonged depletion of guanosine triphosphate induces death of insulin-secreting cells by apoptosis. Endocrinology 139:3752-3762
22. Meredith M, Li G, Metz SA (1997) Inhibition of calcium-induced insulin secretion from intact HIT-T15 or INS-1 beta cells by GTP depletion. Biochem Pharmacol 53:1873-1882
23. Meredith M, Rabaglia M, Metz S (1995) Cytosolic biosynthesis of GTP and ATP in normal rat pancreatic islets. Biochim Biophys Acta 1266:16-22
24. Gillard P, Ling Z, Mathieu C et al (2008) Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts. Transplantation 85:256-263
25. Kaplan B, West P, Neeley H et al (2008) Use of low dose tacrolimus, mycophenolate mofetil and maintenance IL-2 receptor blockade in an islet transplant recipient. Clin Transplant 22:250-253
26. O'Reilly T, McSheehy PM (2010) Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 3:65-79
27. Kirchner GI, Meier-Wiedenbach I, Manns MP (2004) Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43:83-95
28. Sanchez-Fructuoso AI (2008) Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 4:807-819
29. Jeong H, Kaplan B (2007) Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol 2:184-191
30. Mahalati K, Kahan BD (2001) Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 40:573-585
31. Shapiro AM, Lakey JR, Ryan EA et al (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230-238